News

Video

Frontline Therapy for Advanced Renal Cell Carcinoma: Patient Scenario Discussion

Author(s):

Ulka Vaishampayan, MD,Alan Tan, MD

Renowned oncologists discuss the case of a 75-year-old man with advanced renal cell carcinoma, providing insights into evaluation and frontline therapy choices.

Related Videos
Tiago Biachi, MD, PhD
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Douglas W. Sborov, MD, MS
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Related Content
Sandy Srinivas, MD
November 21st 2024

Kidney Cancer NCCN Guidelines Receive Major Updates, Prostate Cancer Adds Targeted Agents

Jaffer A. Ajani, MD, GI medical oncologist, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
November 14th 2024

FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma

RP1 Plus Nivolumab in Advanced Melanoma | Image Credit: © ReisMedia - stock.adobe.com
November 11th 2024

RP1 Plus Nivolumab Is Active, Safe in Advanced Melanoma After Progression on Anti–PD-1 Therapy

Oncology Unplugged
November 6th 2024

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

PD-L1, KIM-1 Expression in ccRCC | Image Credit: © Cornflakesei - stock.adobe.com
November 8th 2024

PD-L1, KIM-1 Expression Are Predictive of Outcomes With Adjuvant Nivolumab Alone, Plus Ipilimumab in ccRCC

BT7480 in Nectin-4+, CD137+ Tumors | Image Credit: © Katsyarina - stock.adobe.com
November 7th 2024

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors